PlainPharmaWatch

CMS Open Payments · Program Year 2024

BioCryst Pharmaceuticals, Inc.

BioCryst Pharmaceuticals, Inc. reported $326,053.24 across General Payments, Research, and Ownership to 188 physicians and teaching hospitals across 188 transactions.

See the rankings → How this is sourced
$326.1K
All-tracks total
188
Transactions
188
Recipients
+$31.9K
General Payments vs PY2023

BioCryst Pharmaceuticals, Inc. reported $326,053.24 across all CMS Open Payments tracks (General + Research + Ownership) to 188 physicians and teaching hospitals in Program Year 2024 - ranking #875 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $326,053.24, averaging $1.7K per recipient.

Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.

Compiled from official public sources by the publisher.

CMS Sunshine Act warrant

Manufacturer biocryst-pharmaceuticals-inc BioCryst Pharmaceuticals, Inc.

$326.1K · #875/1,925 · 0.0% industry · PY2024

  • TOT $326.1K
  • RANK #875
  • SHARE 0.0%
  • TXN 188
  • RCP 188
  • CAT 4
  • GEN $326.1K
  • ΔGEN +$31.9K
  • TOP1 21.2%
  • PY 2024

Volume peers

Nearest volume peer: Brainsway USA INC ($326.1K)

Life Spine, Inc.$327.4KBrainsway USA INC$326.1KBioCryst Pharmaceuticals, In…$326.1KEndogastric Solutions, Inc$325.4KDeGen Medical, Inc.$324.9K
All-tracks payment totals near BioCryst Pharmaceuticals, Inc. (CMS Open Payments PY2024)

BioCryst Pharmaceuticals, Inc. sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →

Release-over-release change

General Payments changed from PY2023 to PY2024

BioCryst Pharmaceuticals, Inc.'s CMS-reported General Payments increased by $31.9K (+10.8%) from PY2023 to PY2024.

How this year-over-year comparison is scoped

The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.

CMS source labels for this exact identifier: PY2022: BIOCRYST PHARMACEUTICALS, INC.PY2023: BIOCRYST PHARMACEUTICALS, INC.PY2024: BioCryst Pharmaceuticals, Inc.. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.

Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.

General Payments: PY2023 vs PY2024

Annual CMS-reported totals for this company, not an all-category Open Payments total

PY2023$294.2KPY2024$326.1K
PY2023
$294,187.70
PY2024
$326,053.24

What the Data Shows for BioCryst Pharmaceuticals, Inc.

Averaging $1.7K per transaction and $1.7K per recipient, BioCryst Pharmaceuticals, Inc.'s Program Year 2024 total comes to $326,053.24 across 188 transactions and 188 physicians and teaching hospitals. In the CMS Open Payments database that is good for rank #875 of 1,925 companies, a comparatively small 0.0% slice of all industry payments reported nationwide for the year.

The 4-category breakdown below covers general payments only (see our methodology for how research and ownership payments are reported separately). The largest general-payment category is "Consulting Fee" at $171.1K, accounting for 52.5% of this company's General Payments and 92 transactions.

General Payment Breakdown by Type

BioCryst Pharmaceuticals, Inc. made 4 types of general payments. "Consulting Fee" is the largest category at $171.1K, 52.5% of General Payments.

BioCryst Pharmaceuticals, Inc. reports 4 general-payment categories - the top three are Consulting Fee (52.5%), Compensation for Services Other Than Consulting (42.0%), and Travel and Lodging (5.0%). The remaining 1 category make up 0.5% of this company's reported general-payment total. That multi-category mix is the kind of profile single-category reporters cannot show.

How BioCryst Pharmaceuticals, Inc. divides its payments

Ranked by total dollars reported per category

1. Consulting Fee$171.1K2. Compensation for Services…$136.9K3. Travel and Lodging$16.4K4. Food and Beverage$1.7K
Payment Type Amount Transactions
Consulting Fee $171.1K 92
Compensation for Services Other Than Consulting $136.9K 37
Travel and Lodging $16.4K 36
Food and Beverage $1.7K 23

Recipient Concentration in General Payments

The five largest recipient relationships account for $201,916.83 (61.9%) of $326,053.24 in this company's General Payments records across 67 recipients.

General Payments scope note

Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.

Largest General-Payment relationships for BioCryst Pharmaceuticals, Inc.

The five named recipients with the highest reported General Payments from this company

Steven Galson$69.1KAmy Mckee$66.7KWendy Yee$32.8KAmer Zeidan$21.0KDonald Fong$12.3K
  1. 1

    Steven Galson

    $69,146.39 across 17 reported transactions

  2. 2

    Amy Mckee

    $66,666.01 across 19 reported transactions

  3. 3

    Wendy Yee

    $32,834.85 across 5 reported transactions

  4. 4

    Amer Zeidan

    $21,000.00 across 1 reported transactions

  5. 5

    Donald Fong

    $12,269.58 across 3 reported transactions

Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.

Similarly Concentrated Companies

Companies whose General Payments are spread across recipients about as (un)evenly as BioCryst Pharmaceuticals, Inc.'s, measured by the same HHI concentration index above, not by payment size.

What HHI 2,500 means here

2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about BioCryst Pharmaceuticals, Inc..

Grifols Shared Services North America, Inc.

HHI 1080

Cook Incorporated

HHI 1081

Cumberland Pharmaceuticals, Inc.

HHI 1083

Vektor Medical Inc.

HHI 1068

Companies with Similar Payment Volumes

Open a profile or compare a similar company's CMS-reported payment pattern with BioCryst Pharmaceuticals, Inc..

Showing 6 of 1,924 companies with CMS-reported payment data.

Data Source: Centers for Medicare & Medicaid Services (CMS) Open Payments, Program Year 2024. Data includes general payments, research payments, and physician ownership/investment interests as required by the Physician Payments Sunshine Act. Total industry payments: $13.9B across 1,925 companies.

Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer

This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

View saved (companies)
Download BioCryst Pharmaceuticals, Inc.'s data (CSV)
Embed this widget

Copy this snippet to embed a live-linked card on your own site.

Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.